Head-to-head · free
Revvity, Inc. vs SOPHiA GENETICS S.A.
RVTY vs SOPH — return on capital, cash generation, margins and balance sheet side by side.
RVTY
2 / 4
measures where RVTY leads
SOPH
2 / 4
measures where SOPH leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | RVTY · FY2025 | SOPH |
|---|---|---|
| Revenue | $2.9B | — |
| Net income | $241.2M | — |
| Revenue growth (yearly, multi-year) | -6.8% | — |
| Free cash flow | $509.4M | — |
| Free cash flow margin | 17.8% | — |
| Net cash / (debt) | — | — |
| ROIC | 2.9% | — |
| Return on equity | 3.2% | -110.0% |
| Gross margin | 54.8% | 67.4% |
| Operating margin | 12.5% | -91.8% |
| Net debt / EBITDA | 3.02x | 0.37x |
Figures are as reported by each company; latest fiscal year shown.
Where Revvity, Inc.'s cash went (FY2025)
- Capital spending
- $73.5M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free